175 related articles for article (PubMed ID: 11351297)
1. Analysis of the molecular species generated by MDM2 gene amplification in liposarcomas.
Tamborini E; Della Torre G; Lavarino C; Azzarelli A; Carpinelli P; Pierotti MA; Pilotti S
Int J Cancer; 2001 Jun; 92(6):790-6. PubMed ID: 11351297
[TBL] [Abstract][Full Text] [Related]
2. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer.
Lukas J; Gao DQ; Keshmeshian M; Wen WH; Tsao-Wei D; Rosenberg S; Press MF
Cancer Res; 2001 Apr; 61(7):3212-9. PubMed ID: 11306511
[TBL] [Abstract][Full Text] [Related]
3. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
5. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
Landers JE; Cassel SL; George DL
Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
[TBL] [Abstract][Full Text] [Related]
6. Alternative and aberrant splicing of MDM2 mRNA in human cancer.
Bartel F; Taubert H; Harris LC
Cancer Cell; 2002 Jul; 2(1):9-15. PubMed ID: 12150820
[TBL] [Abstract][Full Text] [Related]
7. MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas.
Schneider-Stock R; Walter H; Radig K; Rys J; Bosse A; Kuhnen C; Hoang-Vu C; Roessner A
J Cancer Res Clin Oncol; 1998; 124(10):532-40. PubMed ID: 9829856
[TBL] [Abstract][Full Text] [Related]
8. Expression of alternatively and aberrantly spliced transcripts of the MDM2 mRNA is not tumor-specific.
Bartel F; Pinkert D; Fiedler W; Kappler M; Würl P; Schmidt H; Taubert H
Int J Oncol; 2004 Jan; 24(1):143-51. PubMed ID: 14654951
[TBL] [Abstract][Full Text] [Related]
9. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4.
Chandler DS; Singh RK; Caldwell LC; Bitler JL; Lozano G
Cancer Res; 2006 Oct; 66(19):9502-8. PubMed ID: 17018606
[TBL] [Abstract][Full Text] [Related]
10. Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22.
Pilotti S; Della Torre G; Lavarino C; Sozzi G; Minoletti F; Vergani B; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1998 Jun; 185(2):188-90. PubMed ID: 9713346
[TBL] [Abstract][Full Text] [Related]
11. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma.
Dei Tos AP; Doglioni C; Piccinin S; Maestro R; Mentzel T; Barbareschi M; Boiocchi M; Fletcher CD
J Pathol; 1997 Jan; 181(1):8-13. PubMed ID: 9071997
[TBL] [Abstract][Full Text] [Related]
12. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature.
Boltze C; Schneider-Stock R; Jäger V; Roessner A
Pathol Res Pract; 2001; 197(8):563-8. PubMed ID: 11518050
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S
Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792
[TBL] [Abstract][Full Text] [Related]
14. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
[TBL] [Abstract][Full Text] [Related]
15. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection.
Butò S; Pierotti MA; Tamborini E; Della Torre G; Lavarino C; Rilke F; Pilotti S
Diagn Mol Pathol; 1999 Sep; 8(3):125-30. PubMed ID: 10565683
[TBL] [Abstract][Full Text] [Related]
16. Expression of alternatively spliced mdm2 transcripts correlates with stabilized wild-type p53 protein in human glioblastoma cells.
Kraus A; Neff F; Behn M; Schuermann M; Muenkel K; Schlegel J
Int J Cancer; 1999 Mar; 80(6):930-4. PubMed ID: 10074928
[TBL] [Abstract][Full Text] [Related]
17. MDM2 mRNA expression is a favorable prognostic factor in non-small-cell lung cancer.
Ko JL; Cheng YW; Chang SL; Su JM; Chen CY; Lee H
Int J Cancer; 2000 May; 89(3):265-70. PubMed ID: 10861503
[TBL] [Abstract][Full Text] [Related]
18. An alternatively spliced HDM2 product increases p53 activity by inhibiting HDM2.
Evans SC; Viswanathan M; Grier JD; Narayana M; El-Naggar AK; Lozano G
Oncogene; 2001 Jul; 20(30):4041-9. PubMed ID: 11494132
[TBL] [Abstract][Full Text] [Related]
19. Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction.
Miyajima K; Tamiya S; Oda Y; Adachi T; Konomoto T; Toyoshiba H; Masuda K; Tsuneyoshi M
Cancer Lett; 2001 Mar; 164(2):177-88. PubMed ID: 11179833
[TBL] [Abstract][Full Text] [Related]
20. p53 Mutation and MDM2 amplification in human soft tissue sarcomas.
Leach FS; Tokino T; Meltzer P; Burrell M; Oliner JD; Smith S; Hill DE; Sidransky D; Kinzler KW; Vogelstein B
Cancer Res; 1993 May; 53(10 Suppl):2231-4. PubMed ID: 8387391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]